Long-Term Management of RAP Lesions in Clinical Practice: Treatment Efficacy and Predictors of Functional Improvement

Marco Frederico Marques a, João Pedro Marques a, b, João Quadrado Gil a, b, José Costa a, Elisabete Almeida a, Maria da Luz Cachulo a, c, Isabel Pires a, c, João Figueira a, c, Rufino Silva a, c

a Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), b Association for Innovation and Biomedical Research on Light and Image (AIBILI), and c Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal

Key Words
Age-related macular degeneration · Anti-angiogenic agents · Choroidal neovascularization · Neovascular phenotypes · Photodynamic therapy · Ranibizumab · Retinal angiomatous proliferation · Retinal neovascularization · Type 3 neovascularization

Abstract
Purpose: To evaluate the long-term efficacy of ranibizumab in the treatment of retinal angiomatous proliferation (RAP) and to identify predictors of functional outcome. Methods: Retrospective case series comprised 79 eyes of 68 consecutive patients with RAP followed up ≥36 months. Primary end-points were best-corrected visual acuity (BCVA) and central macular thickness (CMT) variation at 36 months and at the last visit. Results: Mean follow-up time was 59.8 ± 16.0 months. All eyes were treated with pro re nata ranibizumab, with (n = 33) or without (n = 46) photodynamic therapy (PDT). Stabilization or improvement in BCVA was observed in 50.6% of the patients at 36 months, and in 40.5% at the end of the follow-up, where 20.3% preserved reading vision. A significant decrease in CMT was observed at 36 months (p < 0.001), but not at the end of the follow-up. Geographic atrophy (GA) was present in 59.5% of the eyes at the final visit. Baseline subretinal fluid was associated with better visual outcomes (p = 0.001). Results of combination treatment with intravitreal ranibizumab and PDT did not significantly differ from ranibizumab monotherapy. Conclusion: Modest functional outcomes can be expected from the long-term treatment of RAP lesions in clinical practice, most likely due to the advent of GA. Baseline subretinal fluid positively correlated with final BCVA.

Introduction
Retinal angiomatous proliferation (RAP), also known as type 3 neovascularization, is a well-recognized neovascular phenotype of age-related macular degeneration (AMD), accounting for 12–15% of its exudative form in Caucasians [1]. The angioproliferative process associated with RAP diverges from other neovascular membranes, as it is believed to start deep within the retina [2–6]. Yannuzzi et al. [7] first classified RAP lesions into three stages according to clinical and angiographic findings: stage 1, intraretinal neovascularization; stage 2, intraretinal plus subretinal neovascularization, and stage 3, choroidal neovascularization.
The advent of optical coherence tomography (OCT), fundus autofluorescence and infrared imaging allowed for a better characterization of the structural changes associated with the disease, such as drusen, reticular pseudodrusen, inner and outer retinal cysts, pigment epithelium detachment (either with or without fibrovascular material), subretinal fluid and geographic atrophy (GA) [8, 9]. The prognostic value of some of these features has been highlighted in several publications [8, 10–12].

RAP has historically been coined a bilaterally aggressive disease with a poor natural history and high relapse rates. While several treatment approaches proved unsuccessful in the past [13–17], the blockage of vascular endothelium growth factor (VEGF) has substantially changed the prognosis of this condition. Reports on intravitreal (IV) ranibizumab, either in monotherapy or with concomitant photodynamic therapy (PDT), have underlined the responsiveness of RAP lesions to both treatment modalities [18–21]. However, standard protocols for the management of the disease are currently not available [1], and published data are limited to small case series with short follow-up periods [18–21].

The purpose of this study was to evaluate the long-term efficacy and safety of IV ranibizumab in eyes with RAP treated in a tertiary care hospital and to identify predictive factors of functional outcome.

Materials and Methods

Population

Retrospective case series included 79 eyes of 68 consecutive RAP patients followed from January 2007 to October 2011. Inclusion criteria were a confirmed diagnosis of RAP based on clinical and angiographic findings and ≥36 months of follow-up after the first IV ranibizumab injection. Patients previously on other AMD treatment formulations, those with a positive past medical history for acute cardiovascular events and those with ophthalmologic conditions likely to jeopardize the clinical assessment were excluded from this analysis. Baseline best-corrected visual acuity (BCVA) was not set as an inclusion or exclusion criterion. Before inclusion, all patients signed an informed consent and the study was conducted according to the tenets of the Declaration of Helsinki.

Clinical Assessment and Imaging

Baseline assessment included a complete ophthalmologic examination complemented with color fundus photography (CFP; fig. 1), fluorescein angiography, indocyanine green angiography and OCT. BCVA was measured according to a standardized refraction protocol using an Early Treatment Diabetic Retinopathy study (ETDRS) chart. Visual enhancement and deterioration were defined as an increase or decrease ≥5 ETDRS letters from baseline, respectively. A stabilized BCVA encompassed any oscillation between those values. Reading vision was classified as a BCVA ≥20/70 (Snellen visual acuity chart) according to the World Health Organization criteria. For standardization purposes, we will refer to this reading vision as an ETDRS equivalent of ≥60 letters. RAP stage at diagnosis was categorized by a senior retina specialist according to the three angiogenic stages defined by Yannuzzi et al.
Before 2009, all OCT images were obtained using the high-resolution 6-radial line protocol of Stratus® OCT (Carl Zeiss Meditec, Dublin, Calif., USA). With the availability of spectral-domain OCT, all further images were acquired using the Spectralis® OCT (Heidelberg Engineering, Heidelberg, Germany). Since both spectral- and time-domain OCT examinations were performed, time-domain OCT grading was calibrated to spectral-domain OCT to minimize potential measurement bias [22]. Identification of GA was based on the presence of >1 patch of >250 μm in the lengthiest linear dimension in CFP within the macula, evidencing >1 of these additional characteristics: sharply delimited boundaries, excavated or punched-out appearance on stereoscopy, enhancement of the choroidal circulation in CFP and correlation with OCT findings. BCVA and central macular thickness (CMT) were recorded during every visit. Adverse events possibly related with IV ranibizumab administration were registered.

Treatment
All patients were treated with IV ranibizumab (Lucentis®, Novartis International AG, Basel, Switzerland), 0.5 mg/0.05 ml, in a nonloading dose pro re nata (PRN) regimen, with (n = 33) or without (n = 46) associated PDT with verteporfin (Visudyne®, Novartis International AG). Decision on retreatment was based on a decrease in BCVA ≥1 ETDRS line and/or OCT findings, specifically the presence of retinal pigment epithelium detachment, hemorrhage, and intra- or subretinal fluid. Each IV injection was performed 3.5–4.0 mm posterior to the corneal limbus using a 30-gauge needle after instillation of topical anesthesia and 5% povidone-iodine solution in the fornix. Prophylaxis of endophthalmitis was achieved with topical quinolone q.i.d. 4 days before and 4 days after the IV injection. PDT was performed only in cases included until December 2009, and discontinued after an intermediate analysis showed no additional benefit versus PRN IV ranibizumab monotherapy. When treating bilateral RAP, IV ranibizumab or PDT were performed on separate days.

End-Points
BCVA and CMT variation at 36 months and at the end of the follow-up were defined as primary end-points of IV ranibizumab efficacy.

Statistical Analysis
All statistical analyses were performed using STATA® version 12.1 (StataCorp LP, College Station, Tex., USA), and p ≤ 0.05 was considered statistically significant. Categorical variables were summarized as frequencies and percentages, and numerical variables as means ± SD and minimum/maximum. The Shapiro-Wilk test was used to assess the normal distribution of continuous variables. The χ² test or Fisher’s exact test was performed to appraise associations between categorical variables, and the Student t test for associations involving independent and paired samples. Mann-Whitney, Wilcoxon, ANOVA and Kruskal-Wallis tests were applied for associations between continuous variables.

Results

Demographics
Seventy-nine eyes from 68 individuals were analyzed; 45 of the patients were females. Mean age at diagnosis was 78.9 ± 7.0 years (range: 60–92 years). Follow-up lasted at least 3 years: 72.2% (n = 57) had ≥4 years and 48.1% (n = 38) ≥5 years, with a mean follow-up of 59.8 ± 16.0 months.

RAP Stage and Neovascularization of the Fellow Eye
According to the classification proposed by Yannuzzi et al. [7], 13 (16.5%) eyes were classified at baseline as stage 1, 31 (39.2%) as stage 2 and 35 (44.3%) as stage 3. Stage 3 eyes presented a significantly lower baseline BCVA when compared to eyes in stage 1 (p = 0.022) or stage 2 (p = 0.010). However, no substantial differences were noticed in the total number of IV ranibizumab injections (p = 0.220) or presence of GA at the final visit (p = 0.206) among the different RAP stages. Thirty-two (41.5%) patients had unaffected fellow eyes at baseline, and 17 (51.3%) of them developed neovascularization during the follow-up.

Visual Acuity
BCVA progression during follow-up and visual outcome at 36 months and at the end of the follow-up are depicted in figures 2 and 3. At diagnosis, 20.3% (n = 16) of the patients were legally blind (≤35 ETDRS letters) and 50.6% (n = 40) presented criteria for low visual acuity (<60 ETDRS letters). A significant increase in BCVA was observed at the 3rd month compared to baseline (p = 0.001). At 36 months, 31.6% of the eyes had improved their BCVA (gain ≥5 letters), 49.4% lost ≥5 letters, and...
in 19.0% there was no significant change (variation <5 ETDRS letters). During the whole length of follow-up, BCVA improved in 22.8%, decreased in 59.5%, and remained stable in 17.7%. At the last visit, 53.2% (n = 42) of the patients were characterized as legally blind, and 26.6% (n = 21) were in the low vision range, whereas 20.3% (n = 16) preserved a BCVA ≥60 ETDRS letters. Thirty-seven eyes (46.8%) lost ≥15 letters during the whole follow-up. Mean BCVA overall variation concerning the first and last visits was –14.0 ± 22.7 (p < 0.001). No significant correlation was found between the total number of IV ranibizumab and the BCVA variation at 36 months (p = 0.966) and at the end of the follow-up (p = 0.721 compared to baseline).

OCT Parameters
Mean CMT progression during follow-up is depicted in figure 4. There was a significant decrease in this parameter after 3 and 36 months compared to baseline (p < 0.001 for both cases). Even though final CMT was still inferior to the mean baseline values, this reduction was not statistically significant (–27.1 ± 163.3 μm, p = 0.095). Sixty-two eyes (78.5%) had intra- and/or subretinal fluid at presentation. This number decreased to 58.2% at the end of the follow-up. A positive correlation was found between the presence of subretinal fluid at presentation and better final BCVA (p = 0.001). From the 79 eyes evaluated, 47 (59.5%) ultimately developed areas of either foveal or extrafoveal GA. No correlation was noticed between the presence of GA in the final visit and final or baseline BCVA, follow-up time or total IV ranibizumab.

Treatment Parameters and Adverse Effects
The mean number of IV ranibizumab injections per patient was 9.2 ± 5.7, representing a mean of 2.2 ± 1.2 injections/patient/year during the whole follow-up period. The highest IV ranibizumab/year ratio was observed in the first 2 years of follow-up: 3.4 ± 1.5 in the 1st year and 2.2 ± 1.4 in the 2nd. Thirty-four patients were treated with a combination of IV ranibizumab and PDT, while 45 un-
derwent IV ranibizumab monotherapy. Between these two groups, no differences regarding visual outcome was found either at 36 months (p = 0.816) or at the end of the follow-up (p = 0.699); sub- or intraretinal fluid at the last visit (p = 0.467 and p = 0.377, respectively); GA development (p = 0.570), or total number of IV ranibizumab injections (p = 0.929) during the whole length of the follow-up. Nine patients (13.2%) experienced vascular adverse effects after starting IV ranibizumab therapy: 7 had ischemic strokes (10.3%). The remaining 2 patients suffered from acute myocardial infarction and pulmonary thromboembolism, respectively. All these patients had at least one systemic cardiovascular risk factor to trigger the incident.

**Discussion**

RAP is believed to have a worse natural history than other subtypes of exudative AMD [23]. Over the past years, the success rate of the various available treatments has been inconsistent. Nevertheless, some authors report relative stabilization of the disease with treatment, either PDT [13, 14] or IV ranibizumab [18, 19, 21]. PDT was combined with IV ranibizumab [18, 24] or even IV triamcinolone [18]. The maximal follow-up of studies on RAP treatment with IV ranibizumab with/without PDT was 3 years [18–21] and small sample sizes were small [18, 19, 24]. To our knowledge, this study combines the longest follow-up (59.8 ± 16.0 months, on average) with the largest sample size (n = 79) on RAP lesions treated with IV ranibizumab published to date.

Our clinical practice results demonstrated that PRN IV ranibizumab regimens can be effective in maintaining or improving BCVA in about half (50.6%) of the treated eyes at 36 months, and in 40.5% after a mean follow-up of approximately 5 years. Remarkably, in about one fifth of our population reading vision was preserved at the last visit. Other studies reported better BCVA results at 2- or 3-year follow-ups [18–20, 24]. One possible explanation could be that the use of anti-VEGF agents in clinical practice rather than in a clinical trial setting [18, 20] may lead to poorer than expected BCVA outcomes: the dependence on the resources and agenda of the clinical center may delay the initiation of treatment, protracting the gap between injections and subsequent follow-up. The treatment regimen – PRN – and other limitations inherent in a clinical practice setting may also have influenced our end-points, and the mean number of injections/patient/year (2.2 ± 1.2) also suggests that our patients may have been undertreated. Furthermore, motivation may differ in a clinical trial, as the expectations of a promising new treatment modality may increase patient compliance for the scheduled visits.

No differences in visual outcome were noticed between the IV ranibizumab and IV ranibizumab plus PDT groups. Our results are in agreement with the ones reported by Rouvas et al. [18], who investigated three treatment arms: IV ranibizumab; IV ranibizumab + PDT, and IV triamcinolone + PDT. Patients were followed for 36 months and presented similar functional outcomes.

In our analysis, a significant reduction in CMT was observed at 3 months, along with a BCVA improvement, and exudation from RAP lesions seems to have regressed swiftly soon after treatment commencement. Other reports also underline this favorable initial response of RAP lesions to treatment [19, 24, 25]. The decrease in CMT between baseline and the 36-month follow-up was still statistically significant in our population. Rouvas et al. [18] also reported significant mean decreases in CMT at 3 and 36 months (last follow-up). In a recent study by Cho et al. [21], a significant decrease in mean CMT was detected after 24 months. In our cohort, CMT did not significantly differ between the last visit and baseline values. This might be explained by our longer mean follow-up time, since the treatment seems to acquire some degree of tachyphylaxis after the initial response. The high percentage of eyes with macular fluid in the final OCT (57.3%) may be a consequence of this effect, which may reflect the final CMT values.

Those patients whose baseline OCT presented subretinal fluid experienced better visual outcomes. According to Einwallner et al. [10], the subretinal fluid plays a role in the prognosis of an exudative lesion because it also reflects its activity. These results suggest that a substantial part of the pathology of AMD is related to inflammatory processes. Ahlers et al. [26] also came to the conclusion that subretinal fluid correlated well with an improvement in BCVA, as well as with the time course of functional recovery. According to these authors, the relationship between subretinal fluid and blood-retina barrier function breakdown may explain these findings, and it may be an important parameter when defining retreatment criteria in the future. Interestingly, a recent study [27] conducted in patients enrolled in CATT (Comparison of AMD Treatments Trials) found that smaller volumes of subretinal fluid are correlated with a higher probability of GA development. Even though this was not observed in our cohort, 27 eyes (34.2%) presented with some degree of GA at baseline, and this number rose to 47 at the last vis-

Long-Term Management of RAP Lesions


DOI: 10.1159/000441797
it (59.5%). McBain et al. [28] reported GA development in 53% (n = 35) of RAP eyes, independently of the treatment chosen (IV anti-VEGF and/or PDT), a result that supports our findings. The aforementioned CATT research group paper [27] also focused on the risk factors for the development of GA and found that the RAP subtype of AMD accounted for a 1.69-fold risk of GA development. The high prevalence of GA in RAP could be explained by decreased choroidal filling in these eyes [29], thus leading to a near-ischemia status. This concept also supports the theory of an intraretinal vascular response in RAP, with budding of outward-growing retinal vessels. This study has several limitations. Its retrospective nature prevents us from controlling variables. For example, follow-up visits should take place at each month but, due to agenda issues, this period of time was seldom respected. A higher number of patients would allow a broader analysis of GA epidemiology, which might yield conclusions with more statistical power. We do believe, however, that these limitations have otherwise a minor impact on our results, given our population’s size and follow-up length.

In conclusion, our long-term follow-up on PRN IV ranibizumab for the treatment of RAP lesions in clinical practice has shown that ∼40% of the eyes had stable or improved BCVA at the end of our long-term follow-up, and about one fifth of the individuals preserved reading vision. Nevertheless, about 60% of the patients presented with some degree of GA at the last visit. The presence of subretinal fluid at baseline was found to positively correlate with a favorable visual outcome, thus appearing to be an important prognostic factor for functional improvement.

Disclosure Statement

R. Silva, MD, PhD, is a member of advisory boards for Allergan, Alimera, Alcon, Bayer, Novartis and Théa. J. Figueira, MD, PhD, is a member of advisory boards for Allergan, Alimera, Alcon, Bayer, Novartis and Kemin.

References


Marques/Marques/Gil/Costa/Almeida/Cachulo/Pires/Figueira/Silva


